ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 113 filers reported holding ALDEYRA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,888,949 | -6.5% | 582,178 | +17.5% | 0.00% | 0.0% |
| Q2 2023 | $4,157,874 | +37338.1% | 495,575 | -55.7% | 0.00% | -66.7% |
| Q1 2023 | $11,106 | +87.7% | 1,118,431 | +31.6% | 0.01% | +100.0% |
| Q4 2022 | $5,917 | -99.8% | 850,088 | +31.5% | 0.00% | +50.0% |
| Q3 2022 | $3,452,000 | -30.1% | 646,394 | -47.7% | 0.00% | -33.3% |
| Q2 2022 | $4,935,000 | +120.1% | 1,236,752 | +145.2% | 0.00% | +200.0% |
| Q1 2022 | $2,242,000 | -69.0% | 504,462 | -72.1% | 0.00% | -66.7% |
| Q4 2021 | $7,236,000 | +104.5% | 1,808,935 | +348.9% | 0.00% | +50.0% |
| Q3 2021 | $3,538,000 | -23.9% | 402,943 | -1.9% | 0.00% | -33.3% |
| Q2 2021 | $4,652,000 | -28.0% | 410,548 | -24.5% | 0.00% | -40.0% |
| Q1 2021 | $6,461,000 | +24.1% | 543,823 | -28.4% | 0.01% | +25.0% |
| Q4 2020 | $5,207,000 | +110.0% | 759,055 | +126.8% | 0.00% | +33.3% |
| Q3 2020 | $2,479,000 | +4.7% | 334,614 | -41.1% | 0.00% | 0.0% |
| Q2 2020 | $2,368,000 | +16.9% | 567,897 | -30.7% | 0.00% | -40.0% |
| Q1 2020 | $2,025,000 | -56.3% | 819,827 | +2.7% | 0.01% | -16.7% |
| Q4 2019 | $4,637,000 | +64.9% | 798,022 | +49.5% | 0.01% | +50.0% |
| Q3 2019 | $2,812,000 | +95.0% | 533,632 | +122.0% | 0.00% | +100.0% |
| Q2 2019 | $1,442,000 | -58.7% | 240,354 | -37.8% | 0.00% | -60.0% |
| Q1 2019 | $3,489,000 | -36.1% | 386,433 | -41.3% | 0.01% | -44.4% |
| Q4 2018 | $5,461,000 | -58.2% | 657,976 | -30.5% | 0.01% | -43.8% |
| Q3 2018 | $13,072,000 | +126.8% | 947,225 | +30.7% | 0.02% | +100.0% |
| Q2 2018 | $5,763,000 | +2.0% | 724,952 | -3.7% | 0.01% | 0.0% |
| Q1 2018 | $5,649,000 | +16.1% | 753,143 | +5.2% | 0.01% | +14.3% |
| Q4 2017 | $4,867,000 | +24.0% | 715,679 | +31.3% | 0.01% | +16.7% |
| Q3 2017 | $3,925,000 | +740.5% | 545,085 | +442.4% | 0.01% | +500.0% |
| Q2 2017 | $467,000 | -9.7% | 100,500 | -2.8% | 0.00% | 0.0% |
| Q1 2017 | $517,000 | -3.4% | 103,385 | +3.4% | 0.00% | 0.0% |
| Q4 2016 | $535,000 | -31.6% | 100,000 | -0.0% | 0.00% | 0.0% |
| Q3 2016 | $782,000 | +5.2% | 100,003 | -23.4% | 0.00% | -50.0% |
| Q2 2016 | $743,000 | +77.3% | 130,500 | +30.4% | 0.00% | +100.0% |
| Q1 2016 | $419,000 | -43.8% | 100,045 | -9.1% | 0.00% | -50.0% |
| Q4 2015 | $746,000 | +10.2% | 110,024 | -5.2% | 0.00% | +100.0% |
| Q3 2015 | $677,000 | -26.7% | 116,100 | -2.4% | 0.00% | -50.0% |
| Q2 2015 | $923,000 | – | 119,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 908,488 | $6,232,000 | 2.88% |
| Knoll Capital Management, LLC | 569,405 | $3,906,000 | 2.66% |
| Mesirow Financial Investment Management, Inc. | 64,698 | $443,828,000 | 1.40% |
| Ghost Tree Capital, LLC | 650,000 | $4,459,000 | 0.99% |
| Johnson & Johnson Innovation - JJDC, Inc. | 594,834 | $4,081,000 | 0.53% |
| Perceptive Advisors | 6,285,458 | $43,118,000 | 0.46% |
| Affinity Asset Advisors, LLC | 100,000 | $686,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 192,500 | $1,321,000 | 0.36% |
| Avidity Partners Management LP | 1,435,000 | $9,844,000 | 0.32% |
| APOGEM CAPITAL LLC | 55,821 | $383,000 | 0.26% |